Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.75 (1.66%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £42.17m
TIME Live PriceLast checked at - London Stock Exchange

Intraday Time Finance Share Chart

Q3 Trading Update

25 Mar 2025 07:00

RNS Number : 8726B
Time Finance PLC
25 March 2025
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

 

25 March 2025

 

Time Finance plc

("Time Finance", the "Group" or the "Company")

 

Q3 TRADING UPDATE

 

Record Lending Book and Record Nine-Month Revenues and Profits Before Tax

 

40% increase in Profit Before Tax over corresponding period; already equal to previous full-year total

 

Time Finance plc, the AIM listed independent specialist finance provider, is pleased to provide a trading update for the nine-month period ended 28 February 2025 ("9M 2024/25"). The Group's strong performance in the first half of the current financial year has been maintained throughout the third quarter. Continued strong demand from UK businesses for the Group's multi-product funding offering has driven further growth in the gross lending book which stands at a record high of more than £210m at the end of February 2025. This is the fifteenth consecutive quarter of loan book growth for the Company.

 

Unaudited Nine Month 2024/25 Highlights

· Own-Book lending origination up 5% to £69.3m (9M 2023/24: £66.0m)

· Revenue up 14% to £27.3m (9M 2023/24: £24.0m)

· Profit before Tax up 40% to £5.9m (9M 2023/24: £4.2m)

· PBT margin improved by 200 bps to 21% (9M 2023/24: 19%)

· Net Tangible Assets up 14% to £43.0m at 28 February 2025 (29 February 2024: £37.7m)

· Gross lending-book up 11% to a record £210m at 28 February 2025 (29 February 2024: £190m)

· Deferred income up 7% to £26.4m at 28 February 2025 (29 February 2024: £24.6m) providing strong visibility of future earnings

· Net Arrears improved to 5% of the gross lending book at 28 February 2025 (29 February 2024: 6%)

· Net Bad Debt Write-Offs unchanged at 1% of the average lending book at 28 February 2025 (29 February 2024: 1%)

· Continuing positive trading momentum; leading to expectation that Group financial performance for the full year will be at least in line with recently upgraded market guidance provided in February 2025[1]

 

A key element of the Company's four-year strategic plan through to 31 May 2025 has been to focus on more secured lending. This was to be achieved primarily though the provision of Invoice Finance and the 'Hard' element of Asset Finance. These two core areas have accounted for 91% of new lending volume originated in the nine months of trading to 28 February 2025, and now make up 81% of the total lending book. This compares to 51% of new deal volume origination and 52% of the total lending book prior to the strategy launch.

 

Ed Rimmer, Chief Executive Officer commented:

"With three quarters of the current financial year now delivered, the Board is very encouraged by the Group's financial performance. To be able to report all-time record nine-month levels of both Revenue and Profit Before Tax is particularly pleasing. As is the fact that the profit generated in the first nine months of the current financial year has already surpassed the level achieved for the whole of the previous year. To have made these strides forward without compromising on credit quality, as shown by the consistent and stable nature of our arrears and our write-offs, is another key performance indicator that we are proud of.

 

"As a result of all these factors, as we close-out the current four-year strategy and enter our new three-year growth trajectory through to May 2028, the Board has real confidence that the Group remains well placed to continue building long-term value for all our shareholders."

 

Investor Presentation

The Company will deliver a live presentation relating to this 9M 2024/25 Trading Update via the Investor Meet Company platform at 1:00pm GMT today. Existing and potential shareholders can sign up to Investor Meet Company for free and add to meet Time Finance plc via: https://www.investormeetcompany.com/time-finance-plc/registerinvestor.

 

For further information, please contact:

 

Time Finance plc

Ed Rimmer, Chief Executive Officer

01225 474230

James Roberts, Chief Financial Officer

Cavendish Capital Markets (NOMAD and Broker)

0207 220 0500

Ben Jeynes / Dan Hodkinson (Corporate Finance)

Michael Johnson / George Budd / Charlie Combe (Sales and ECM)

Walbrook PR

0207 933 8780

Nick Rome / Joe Walker

Timefinance@walbrookpr.com

 

About Time Finance:

Time Finance's purpose is to help UK businesses thrive and survive through the provision of flexible funding facilities. It offers a multi-product range for SMEs primarily concentrating on Asset Finance and Invoice Finance. While focussed on being an 'own-book' lender, the Group does retain the ability to broke-on deals where appropriate, enabling it to optimize business levels through market and economic cycles.

 

More information is available on the Company website: www.timefinance.com.

 


1 FY2024/25 market expectations were upgraded on 27th February 2025 to £36.0m of Revenue and £7.5m of Profit Before Tax.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIIVTISFIE
Date   Source Headline
21st Sep 20217:00 amRNS2021 Final Results
7th Sep 20217:00 amRNSNotice of Final Results and Investor Presentation
16th Jun 20217:00 amRNSYear-end Trading Update
10th Jun 20217:00 amRNSPermanent CEO Appointment & Investor Presentation
4th Jun 202111:30 amRNSHolding(s) in Company
4th Jun 202111:25 amRNSHolding(s) in Company
27th May 20215:29 pmRNSEmployee Benefit Trust Share Purchase
27th May 20217:00 amRNSExercise of Options
21st May 20217:00 amRNSUnapproved Share Option Scheme – Vesting of Awards
6th May 20217:00 amRNSNew Loan Accreditation & Financial Calendar Update
22nd Apr 20217:00 amRNSCorporate Update
9th Apr 20212:58 pmRNSEmployee Benefit Trust Share Purchase
26th Mar 20217:00 amRNSDirectorate Change
3rd Mar 20217:00 amRNSFurther re Directorate Change
19th Feb 202112:04 pmRNSDirectorate Changes
3rd Feb 20217:00 amRNSTechnology Infrastructure Update
19th Jan 20217:00 amRNSInterim Results
12th Jan 20217:00 amRNSHolding in Company
12th Jan 20217:00 amRNSHolding in Company
6th Jan 20217:00 amRNSDirectorate Changes
15th Dec 20205:15 pmRNSTR-1: Holding in Company - CORRECTION
9th Dec 20207:00 amRNSHalf Year Trading Update & Investor Presentation
1st Jun 20103:19 pmRNSResult of EGM
28th May 20107:00 amRNSUpdate
6th May 20108:37 amRNSStrategic Review - update
6th May 20107:01 amRNSNotice of EGM
6th May 20107:00 amRNSAppointment of adviser
4th May 201011:22 amRNSForm 8.3 - Timestrip PLC
4th May 20107:00 amRNSForm 8 (OPD) Timestrip
19th Apr 20107:30 amRNSStrategic Review Update and Suspension
19th Apr 20107:30 amRNSSuspension - Timestrip plc
24th Mar 20109:50 amRNSRule 8.1- (Timestrip)
19th Mar 201012:47 pmRNSStrategic Review - Update
18th Mar 20107:00 amRNSStrategic Review
5th Feb 20109:04 amRNSDirectorate Change
3rd Feb 20104:29 pmRNSAIM Rule 17
1st Feb 20107:00 amRNSContract Win - Toothbrush Order
5th Nov 200912:23 pmRNSUK Packaging Awards
28th Oct 20097:00 amRNSTimestrip IV - First full adoption by NHS Trust
26th Oct 20097:00 amRNSTimestrip Medical - 1st order in North America
14th Sep 20097:01 amRNSHalf Yearly Report
14th Sep 20097:00 amRNSNHS trials and appointment of distributor
24th Jul 20092:18 pmRNSResult of AGM
6th Jul 20097:00 amRNSNew distribution agreement
1st Jul 20097:00 amRNSPreliminary findings on Timestrip IV
29th Jun 20091:26 pmRNSNotice of AGM
11th Jun 20097:00 amRNSFinal Results
8th May 20097:00 amRNSIssue of Equity
5th May 20097:00 amRNSLuton & Dunstable Hospital orders TimestripIV
28th Apr 20097:00 amRNSTimestripIV showcased in NHS funded project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.